About Hibiskus
Hibiskus is a company based in Kalamazoo (United States) founded in 2017 by Andre Bachmann and Michael Pirrung was acquired by Lodo Therapeutics in September 2020. Hibiskus operates in a competitive market with competitors including Jazz Pharmaceuticals, Revolution Medicines, Blueprint Medicines, Syndax and C4 Therapeutics, among others.
- Headquarter Kalamazoo, United States
- Founders Andre Bachmann, Michael Pirrung
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Latest Funding Round
Not available
- Investors
-
Employee Count
Not available
-
Acquired by
Lodo Therapeutics
(Sep 03, 2020)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Hibiskus
Detailed funding history for Hibiskus
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investors in Hibiskus
Hibiskus has secured backing from 1 investor. Prominent investors backing the company include Lodo Therapeutics.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Developer novel therapeutics to treat resistant infectious diseases and cancers using AI
|
Locked | Locked | Locked |
Investor details for Hibiskus
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Hibiskus
Investment portfolio details for Hibiskus
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Hibiskus
Detailed financials for Hibiskus
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Hibiskus Comparisons
Peer comparison for Hibiskus
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Hibiskus
Hibiskus operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Revolution Medicines, Blueprint Medicines, Syndax and C4 Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Cancer therapies are developed using selective pathway inhibitors.
|
|
| Locked | Locked | Locked |
Selective kinase inhibitors are developed for genomically defined cancers.
|
|
| Locked | Locked | Locked |
Targeted therapies for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
|
|
| Locked | Locked | Locked |
Small molecule therapeutics for cancer treatment are developed.
|
Detailed competitors of Hibiskus
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Hibiskus
Complete news archive for Hibiskus
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Hibiskus
Hibiskus was founded in 2017.
Hibiskus is headquartered in Kalamazoo, United States. It is registered at Kalamazoo, Michigan, United States.
Hibiskus Biopharma is a developer of small-molecule therapeutic solutions for cancer treatment. It has developed TIR-199 drugs that work as a potent proteasome inhibitor from the syrbactin natural product family. The product contains a proteasome inhibitor that helps to induce cell death of tumor cell types. It inhibits the digestive function of proteasomes which induces a cytotoxic buildup of cellular proteins that activates apoptotic pathways. It has developed FDA-approved drugs, target multiple myeloma, antibodies that produce cells in the blood others. Features include high-potency against proteasome activity cellular proliferation indicating a superior safety profile, induces cell death, and others.
Hibiskus's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and argenx.
Hibiskus has 1 investor. Key investors include Lodo Therapeutics.